

Company name: KYORIN Holdings, Inc.

Representative: Masahiro Yamashita

Representative Director, President

(Securities Code: 4569, TSE 1st Sec.)

Application filed for KRP-108, an Anti-asthmatic Treatment, in Japan

TOKYO, Japan (September 25, 2012) —Kyorin Pharmaceutical Co., Ltd. ("Kyorin") (Tokyo, Japan, President: Mitsutomo Miyashita), a wholly owned subsidiary of KYORIN Holdings, Inc., has filed a new drug application for KRP-108, a drug for asthma treatment .

KRP-108, developed by SkyePharma PLC (United Kingdom, CEO: Peter Grant), is a fixed-dose combination of formoterol fumarate and fluticasone propionate; those micronized particles suspended in a propellant in a metered dose inhaler. The same product is now approved, as *flutiform*[®], in eight European countries to date where its approval was supported by clinical studies, which were conducted in a patient population of approximately 5,000, of whom 1,900 received *flutiform*[®].

Since licensing from SkyePharma PLC on April 22, 2008 exclusive rights in Japan for clinical development, sales and marketing of KRP-108, Kyorin has developed KRP-108 in Japan, with additional clinical studies, leading to the registration application.

Kyorin will make efforts to expedite the approval of KRP-108 in Japan and to contribute increasing the benefits provided to patients living with asthma by further expanding its lineup of respiratory products.

For Reference

About KRP-108

Active ingredients: Fluticasone propionate (inhaled corticosteroid: ICS) and formoterol fumarate (long-acting beta-agonist: LABA)

Indication: Bronchial asthma (when a combination of an inhaled steroid and a long-acting inhaled β 2agonist is necessary)

Originated by: SkyePharma PLC

Features:

- 1) An ICS/LABA combination product, which offers convenience and better compliance of the patients.
- 2) Materializes ideal combination of potent ICS and rapid, long-lasting LABA.
- 3) MDI device offers several advantages such as reproducible doses per actuation and suitability to patients with lowered respiratory effort.

About SkyePharma PLC

Established in: March 1910 (renamed to present company name in January 1996)

CEO: Peter Grant

Location: 46-48 Grosvenor Gardens, London SW1W 0EB, United Kingdom

Revenue: £55.2 million (2011)

Number of employees: 158 (2011 average)

Features: SkyePharma, a London-based pharmaceutical company, uses its multiple drug delivery technologies and expertise to create enhanced versions of pharmaceutical products. The Group receives revenues from thirteen approved products in the areas of inhalation, oral, topical and injectable delivery as well as generating income from the development of further products and technology licenses. The Group's products are marketed throughout the world by leading pharmaceutical companies.